《新股消息》云顶新耀(01952.HK)今日起招股 入场费27,777元
生物制药公司云顶新耀(01952.HK)公布招股详情,计划发行6,354.7万股,当中约10%在港公开发售,集资最多34.95亿,招股价介乎50至55元,一手500股,入场费为27,777.12元。由今日(25日)至下周三(30日)公开招股,预计於10月9日上市。高盛及美银证券为联席保荐人。
以招股价中位数52.5元计,公司预计集资净额为31.32亿元,当中将60%用於为集团四款支柱产品的进行中及计划临床试验、登记备案准备及有关商业化的其他步骤或活动提供资金;15%为其他候选药物的进行中及计划临床试验、登记备案准备及潜在商业化提供资金;15%用於业务发展活动及扩展药品管线提供资金;以及10%用作营运资金以及一般及行政用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.